Baxter International Inc (BAX) 35.60 $BAX
Baxter International Set to Possibly Pullback After Yesterday's Rally of 3.91%
Comtex SmarTrend(R) - Wed Oct 21, 4:04PM CDT
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $34.41 to a high of $35.68. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $34.50 on volume of 12.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 35.60 (+1.34)
Baxter International (BAX) Approaches New Upside Target of $34.84
Comtex SmarTrend(R) - Wed Oct 21, 10:47AM CDT
Shares of Baxter International (NYSE:BAX) opened today above their pivot of $34.21 and have already reached the first level of resistance at $34.55. Should the shares continue to rise, the resistance pivots of $34.84 and $35.46 will be of interest.
BAX: 35.60 (+1.34)
St. Jude Medical Q3 Earnings Meet, Currency Woes Prevail
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 10:30AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings of 97 cents in third-quarter 2015, which were in line with the Zacks Consensus Estimate.
SRDX: 21.26 (-0.62), BAX: 35.60 (+1.34), STJ: 62.30 (-6.06), NUVA: 48.61 (-1.31)
Baxter Appoints Michael F. Mahoney to Its Board
Business Wire - Wed Oct 21, 8:00AM CDT
Baxter International Inc. (NYSE:BAX) today announced it has appointed to Baxter's Board of Directors Michael F. Mahoney, president and chief executive officer of Boston Scientific Corporation. Mahoney will serve on Baxter's corporate governance and compensation committees.
BSX: 17.19 (unch), BAX: 35.60 (+1.34)
Leading 200 Global Medical Devices/Technology/Supplies Company Analysis 2015 - News, Financial/Non-Financial Information, and Stock Market Analysis
M2 - Wed Oct 21, 2:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5th588/global_most) has announced the addition of the "Global Most International Medical Devices/Technology/Supplies 200 " report to their offering. This newly launched report identifies 200 Most International medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. In today's rapidly changing business climate, understanding the regulatory and demographic environment of the medical industry is only part of the challenge. The real struggle for medical device companies is defining the right strategy, particularly with increasing consolidation, heightened regulation, and shifting market demands. Firms that are able to adapt quickly, taking advantage of the transformative nature of the industry, will become inherent market leaders. There are many companies in the medical devices/technology/supplies industry that have presence in many countries worldwide. Since last few years, these companies have established and expanded their presence in global markets. Such companies are dedicated to improving people's health throughout the world. These companies have global marketing and sales capabilities with a presence in many countries worldwide. Highlights - Leading 200 Most Global medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Most Global medical devices/technology/supplies companies - International presence of Most Global medical devices/technology/supplies companies - Key R&D activities by Most Global medical devices/technology/supplies companies Key Topics Covered: nalysis Section: 1: Rankings of Most Global Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Most Global Medical Devices/Technology/Supplies Companies with Most Increases News Section: 3: Key News of Most Global Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Most Global Medical Devices/Technology/Supplies Companies 5: Research and Development Activities by Most Global Medical Devices/Technology/Supplies Companies 6: International Presence of Most Global Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Most Global Medical Devices/Technology/Supplies Companies Sample list of company names included in this industry report: - 3 D Matrix Ltd (Japan) - 3M Company (United States) - aap Implantate AG (Germany) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Accuray Inc (United States) - Alphatec Holdings, Inc. (United States) - Ambu A/S (Denmark) - Amplifon SpA (Italy) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - Carl Zeiss Meditec AG (Germany) - Cepheid (United States) - Cochlear Limited (Australia) - Coherent Incorporated (United States) - Draegerwerk AG & Co KGaA (Germany) - Fresenius Medical Care AG & Co. KGaA (Germany) - Hitachi High Technologies Corp (Japan) - Impedimed Limited (Australia) - Masimo Corporation (United States) - Nitto Denko (Japan) - Osim International Limited (Singapore) - Sonova Holding AG (Switzerland) - Stratec Biomedical AG (Germany) - Zimmer Holdings, Inc. (United States) For more information visit http://www.researchandmarkets.com/research/5t...lobal_most
ZMH: 113.56 (+0.29), MMM: 149.82 (+0.71), ATEC: 0.32 (-0.01), MASI: 40.70 (-0.70), ARAY: 5.42 (+0.04), BSX: 17.19 (unch), ABAX: 43.88 (-1.73), BAX: 35.60 (+1.34), CPHD: 30.02 (-2.23), COHR: 53.72 (-1.66)
Downtrend Call Working As Baxter International Stock Falls 15.0% (BAX)
Comtex SmarTrend(R) - Tue Oct 20, 5:00PM CDT
SmarTrend identified a Downtrend for Baxter International (NYSE:BAX) on August 19th, 2015 at $40.32. In approximately 2 months, Baxter International has returned 15.03% as of today's recent price of $34.26.
BAX: 35.60 (+1.34)
CVS Pharmacy: New Support Program for Healthcare Coverage
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 1:30PM CDT
CVS/pharmacy ??? the retail division of CVS Health (CVS) ??? introduced a complete set of health insurance tools, resources and information.
WBA: 88.04 (-0.70), BAX: 35.60 (+1.34), CVS: 103.29 (-0.31), NUVA: 48.61 (-1.31)
20th Software Design for Medical Devices Summit in Boston to be Chaired by Phani Bidarahalli, Wipro
PR Newswire - Tue Oct 20, 10:20AM CDT
IQPC's 20th Software Design for Medical Devices Summit is pleased to announce that Mr. Phani Bidarahalli, GM & Head of Healthcare Engineering at Wipro will be chairing the summit.
WIT: 11.92 (-0.37), MDT: 73.42 (-0.22), BAX: 35.60 (+1.34), EW: 148.91 (-2.29)
Cardiovascular Systems (CSII) Worth a Look: Stock Up 6.8%
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 7:45AM CDT
Cardiovascular Systems Inc. (CSII) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
CSII: 14.58 (+0.08), BAX: 35.60 (+1.34)
Global Product and Pipeline Analysis of the Immunoglobulin Market 2015 - Trends in Communicable and Non-Communicable Diseases Drug Pipeline
M2 - Mon Oct 19, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p9pjbz/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Global Immunoglobulin Market" report to their offering. Immunoglobulin therapies are life-saving medicines that have been in use for more than 60 years. They provide the patient with a variety of antibodies and are often used as a last line of defense in many severe inflammatory diseases. In some conditions, they are life-saving. However, immunoglobulin therapies are expensive. Despite this, global demand for immunoglobulin is growing and the market is expected to foresee increased competition. As of 2015, more than 40 immunoglobulin treatments have been approved, with another 28 in various stages of development. This research service provides an overview of the marketed products and those in the pipeline. The analysis divides these treatments by the communicable and non-communicable diseases that they treat. In addition, key products and companies are profiled. Key Topics Covered: 1. Executive Summary - Key Findings - Major Milestones - Scope of the Study 2. Introduction to the Immunoglobulin Market - Immunoglobulin Overview - Classification of Immunoglobulins - Treatment Guidelines - Market Overview 3. Immunoglobulin Market - Marketed and Pipeline Products - Overview of Drugs - Competitive Landscape - Communicable Diseases Treatments - Competitive Landscape - Non-Communicable Diseases Treatments 4. Communicable Diseases Product Analysis - Communicable Diseases Product Overview - Marketed Product Analysis - Pipeline Product Analysis 5. Non-Communicable Diseases Product Analysis - Non-Communicable Diseases Product Overview - Marketed Product Analysis - Pipeline Product Analysis 6. Immunoglobulin MarketProduct Dashboards - Hizentra - CSL Behring - Civacir - Biotest - Flebogamma 10% - Grifols - GAMUNEX-C - Grifols - Privigen - CSL Behring - VariZIG - Cangene - Hepabulin IV - SK Holdings - Zutectra - Biotest - HyperTET - Grifols 7. Key Companies in the Immunoglobulin Market - Baxter International Inc. - Biotest AG - China Biologics Products, Inc. - CSL Behring Limited - Grifols - Octapharma AG - Kedrion Biopharma 8. Immunoglobulin Market - Timeline of Key Events - Estimated Key Product Launch Timeline - Approval Dates 9. Future of the Immunoglobulin Market For more information visit http://www.researchandmarkets.com/research/p9...roduct_and
BAX: 35.60 (+1.34)
VWR Corp: Multiple Initiatives Drive Consistent Global Growth
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:40PM CDT
On Oct 16, 2015, we initiated a research report on VWR Corporation (VWR).
VWR: 26.57 (-0.11), BAX: 35.60 (+1.34), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Kamada Announces Third Extension of Strategic Agreement with Baxalta
Business Wire - Fri Oct 16, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the third extension to supply Glassia(R) to Baxalta (NYSE:BXLT), which recently separated from Baxter International, Inc. (Baxter), under its strategic agreement with Baxter originally executed in August 2010. Through the extended agreement, Kamada secured approximately $50 million in additional minimum revenues of Glassia, the Company's proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency (AATD), through 2018. As a result, Kamada expects that total revenue generated through this agreement from August 2010 through end of 2018 will increase to a minimum of $240 million compared with a minimum of $110 million in the original agreement executed in 2010 and a minimum of $191 million in the September 2014 extension of that agreement.
BAX: 35.60 (+1.34), KMDA: 3.97 (+0.09), BXLT: 31.73 (-0.36)
BioScrip Works on New Strategies, Margin Concerns Stay
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 1:15PM CDT
On Sep 14, we issued an updated research report on Bioscrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
BAX: 35.60 (+1.34), BIOS: 1.93 (-0.04), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Medtronic Unveils Favorable CoreValveEvolut R Study Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 1:10PM CDT
Medtronic plc (MDT) recently received favorable one-year data for its renowned transcatheter aortic valve replacement (TAVR) using the CoreValveEvolut R System.
MDT: 73.42 (-0.22), BAX: 35.60 (+1.34), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Baxter International Inc. Securities Litigation
PR Newswire - Thu Oct 15, 12:38PM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Baxter International Inc. Securities Litigation:
BAX: 35.60 (+1.34)
2 Top Stock Picks From Superstar Hedge Fund Investor Dan Loeb
at The Street - Thu Oct 15, 12:07PM CDT
Third Point's wily activist, known for blunt talk and stellar returns, has doubled down on Baxter International (BAX) and Mohawk Industries (MHK) this year.
BDX: 139.76 (unch), BCR: 189.65 (-2.72), MHK: 195.01 (-0.91), BAX: 35.60 (+1.34), BXLT: 31.73 (-0.36), BRK.B: 133.22 (-0.94), BRK.A: 199,900.00 (-1,580.00)
Baxter (BAX) Receives FDA Clearance for AMIA APD System
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 11:30AM CDT
Baxter International Inc. (BAX) recently announced that the FDA has approved its AMIA automated peritoneal dialysis (APD) system with the SHARESOURCE web-based remote connectivity platform.
NXTM: 15.55 (-0.18), BAX: 35.60 (+1.34), FMS: 42.31 (unch), NUVA: 48.61 (-1.31)
MacroGenics (MGNX) Looks Good: Stock Moves 5.5% Higher
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 7:40AM CDT
MacroGenics, Inc. (MGNX) saw its shares rise nearly 6% in the last trading session.
MGNX: 29.15 (+0.44), BAX: 35.60 (+1.34)
Shares of BAX Down 17.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 13, 11:35AM CDT
SmarTrend identified a Downtrend for Baxter International (NYSE:BAX) on August 19th, 2015 at $40.32. In approximately 2 months, Baxter International has returned 17.18% as of today's recent price of $33.40.
BAX: 35.60 (+1.34)
These Big Pharma Companies Are in Need of an Acquisition
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 13, 7:45AM CDT
Source: Flickr user Nguyen Hung Vu. Although we're officially over the "patent cliff" -- the multiple year period when dozens of innovator drugs came off patent and were exposed to generic competition -- Big Pharma is far from out of the woods when...
JNJ: 97.63 (+0.04), ISIS: 42.97 (+1.64), BAX: 35.60 (+1.34), PFE: 33.46 (-0.54), AZN: 30.47 (-0.46), ABBV: 53.83 (-1.00), BXLT: 31.73 (-0.36), GSK: 40.86 (-0.30), NVS: 91.59 (-0.74)
Baxter International Set to Possibly Pullback After Yesterday's Rally of 3.91%
Comtex SmarTrend(R) - Wed Oct 21, 4:04PM CDT
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $34.41 to a high of $35.68. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $34.50 on volume of 12.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 35.60 (+1.34)
Baxter International (BAX) Approaches New Upside Target of $34.84
Comtex SmarTrend(R) - Wed Oct 21, 10:47AM CDT
Shares of Baxter International (NYSE:BAX) opened today above their pivot of $34.21 and have already reached the first level of resistance at $34.55. Should the shares continue to rise, the resistance pivots of $34.84 and $35.46 will be of interest.
BAX: 35.60 (+1.34)
St. Jude Medical Q3 Earnings Meet, Currency Woes Prevail
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 10:30AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings of 97 cents in third-quarter 2015, which were in line with the Zacks Consensus Estimate.
SRDX: 21.26 (-0.62), BAX: 35.60 (+1.34), STJ: 62.30 (-6.06), NUVA: 48.61 (-1.31)
Baxter Appoints Michael F. Mahoney to Its Board
Business Wire - Wed Oct 21, 8:00AM CDT
Baxter International Inc. (NYSE:BAX) today announced it has appointed to Baxter's Board of Directors Michael F. Mahoney, president and chief executive officer of Boston Scientific Corporation. Mahoney will serve on Baxter's corporate governance and compensation committees.
BSX: 17.19 (unch), BAX: 35.60 (+1.34)
Leading 200 Global Medical Devices/Technology/Supplies Company Analysis 2015 - News, Financial/Non-Financial Information, and Stock Market Analysis
M2 - Wed Oct 21, 2:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5th588/global_most) has announced the addition of the "Global Most International Medical Devices/Technology/Supplies 200 " report to their offering. This newly launched report identifies 200 Most International medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. In today's rapidly changing business climate, understanding the regulatory and demographic environment of the medical industry is only part of the challenge. The real struggle for medical device companies is defining the right strategy, particularly with increasing consolidation, heightened regulation, and shifting market demands. Firms that are able to adapt quickly, taking advantage of the transformative nature of the industry, will become inherent market leaders. There are many companies in the medical devices/technology/supplies industry that have presence in many countries worldwide. Since last few years, these companies have established and expanded their presence in global markets. Such companies are dedicated to improving people's health throughout the world. These companies have global marketing and sales capabilities with a presence in many countries worldwide. Highlights - Leading 200 Most Global medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Most Global medical devices/technology/supplies companies - International presence of Most Global medical devices/technology/supplies companies - Key R&D activities by Most Global medical devices/technology/supplies companies Key Topics Covered: nalysis Section: 1: Rankings of Most Global Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Most Global Medical Devices/Technology/Supplies Companies with Most Increases News Section: 3: Key News of Most Global Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Most Global Medical Devices/Technology/Supplies Companies 5: Research and Development Activities by Most Global Medical Devices/Technology/Supplies Companies 6: International Presence of Most Global Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Most Global Medical Devices/Technology/Supplies Companies Sample list of company names included in this industry report: - 3 D Matrix Ltd (Japan) - 3M Company (United States) - aap Implantate AG (Germany) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Accuray Inc (United States) - Alphatec Holdings, Inc. (United States) - Ambu A/S (Denmark) - Amplifon SpA (Italy) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - Carl Zeiss Meditec AG (Germany) - Cepheid (United States) - Cochlear Limited (Australia) - Coherent Incorporated (United States) - Draegerwerk AG & Co KGaA (Germany) - Fresenius Medical Care AG & Co. KGaA (Germany) - Hitachi High Technologies Corp (Japan) - Impedimed Limited (Australia) - Masimo Corporation (United States) - Nitto Denko (Japan) - Osim International Limited (Singapore) - Sonova Holding AG (Switzerland) - Stratec Biomedical AG (Germany) - Zimmer Holdings, Inc. (United States) For more information visit http://www.researchandmarkets.com/research/5t...lobal_most
ZMH: 113.56 (+0.29), MMM: 149.82 (+0.71), ATEC: 0.32 (-0.01), MASI: 40.70 (-0.70), ARAY: 5.42 (+0.04), BSX: 17.19 (unch), ABAX: 43.88 (-1.73), BAX: 35.60 (+1.34), CPHD: 30.02 (-2.23), COHR: 53.72 (-1.66)
Downtrend Call Working As Baxter International Stock Falls 15.0% (BAX)
Comtex SmarTrend(R) - Tue Oct 20, 5:00PM CDT
SmarTrend identified a Downtrend for Baxter International (NYSE:BAX) on August 19th, 2015 at $40.32. In approximately 2 months, Baxter International has returned 15.03% as of today's recent price of $34.26.
BAX: 35.60 (+1.34)
CVS Pharmacy: New Support Program for Healthcare Coverage
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 1:30PM CDT
CVS/pharmacy ??? the retail division of CVS Health (CVS) ??? introduced a complete set of health insurance tools, resources and information.
WBA: 88.04 (-0.70), BAX: 35.60 (+1.34), CVS: 103.29 (-0.31), NUVA: 48.61 (-1.31)
20th Software Design for Medical Devices Summit in Boston to be Chaired by Phani Bidarahalli, Wipro
PR Newswire - Tue Oct 20, 10:20AM CDT
IQPC's 20th Software Design for Medical Devices Summit is pleased to announce that Mr. Phani Bidarahalli, GM & Head of Healthcare Engineering at Wipro will be chairing the summit.
WIT: 11.92 (-0.37), MDT: 73.42 (-0.22), BAX: 35.60 (+1.34), EW: 148.91 (-2.29)
Cardiovascular Systems (CSII) Worth a Look: Stock Up 6.8%
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 7:45AM CDT
Cardiovascular Systems Inc. (CSII) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
CSII: 14.58 (+0.08), BAX: 35.60 (+1.34)
Global Product and Pipeline Analysis of the Immunoglobulin Market 2015 - Trends in Communicable and Non-Communicable Diseases Drug Pipeline
M2 - Mon Oct 19, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p9pjbz/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Global Immunoglobulin Market" report to their offering. Immunoglobulin therapies are life-saving medicines that have been in use for more than 60 years. They provide the patient with a variety of antibodies and are often used as a last line of defense in many severe inflammatory diseases. In some conditions, they are life-saving. However, immunoglobulin therapies are expensive. Despite this, global demand for immunoglobulin is growing and the market is expected to foresee increased competition. As of 2015, more than 40 immunoglobulin treatments have been approved, with another 28 in various stages of development. This research service provides an overview of the marketed products and those in the pipeline. The analysis divides these treatments by the communicable and non-communicable diseases that they treat. In addition, key products and companies are profiled. Key Topics Covered: 1. Executive Summary - Key Findings - Major Milestones - Scope of the Study 2. Introduction to the Immunoglobulin Market - Immunoglobulin Overview - Classification of Immunoglobulins - Treatment Guidelines - Market Overview 3. Immunoglobulin Market - Marketed and Pipeline Products - Overview of Drugs - Competitive Landscape - Communicable Diseases Treatments - Competitive Landscape - Non-Communicable Diseases Treatments 4. Communicable Diseases Product Analysis - Communicable Diseases Product Overview - Marketed Product Analysis - Pipeline Product Analysis 5. Non-Communicable Diseases Product Analysis - Non-Communicable Diseases Product Overview - Marketed Product Analysis - Pipeline Product Analysis 6. Immunoglobulin MarketProduct Dashboards - Hizentra - CSL Behring - Civacir - Biotest - Flebogamma 10% - Grifols - GAMUNEX-C - Grifols - Privigen - CSL Behring - VariZIG - Cangene - Hepabulin IV - SK Holdings - Zutectra - Biotest - HyperTET - Grifols 7. Key Companies in the Immunoglobulin Market - Baxter International Inc. - Biotest AG - China Biologics Products, Inc. - CSL Behring Limited - Grifols - Octapharma AG - Kedrion Biopharma 8. Immunoglobulin Market - Timeline of Key Events - Estimated Key Product Launch Timeline - Approval Dates 9. Future of the Immunoglobulin Market For more information visit http://www.researchandmarkets.com/research/p9...roduct_and
BAX: 35.60 (+1.34)
VWR Corp: Multiple Initiatives Drive Consistent Global Growth
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:40PM CDT
On Oct 16, 2015, we initiated a research report on VWR Corporation (VWR).
VWR: 26.57 (-0.11), BAX: 35.60 (+1.34), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Kamada Announces Third Extension of Strategic Agreement with Baxalta
Business Wire - Fri Oct 16, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the third extension to supply Glassia(R) to Baxalta (NYSE:BXLT), which recently separated from Baxter International, Inc. (Baxter), under its strategic agreement with Baxter originally executed in August 2010. Through the extended agreement, Kamada secured approximately $50 million in additional minimum revenues of Glassia, the Company's proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency (AATD), through 2018. As a result, Kamada expects that total revenue generated through this agreement from August 2010 through end of 2018 will increase to a minimum of $240 million compared with a minimum of $110 million in the original agreement executed in 2010 and a minimum of $191 million in the September 2014 extension of that agreement.
BAX: 35.60 (+1.34), KMDA: 3.97 (+0.09), BXLT: 31.73 (-0.36)
BioScrip Works on New Strategies, Margin Concerns Stay
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 1:15PM CDT
On Sep 14, we issued an updated research report on Bioscrip, Inc. (BIOS) ??? provider of home infusion and pharmacy benefit management (PBM) services.
BAX: 35.60 (+1.34), BIOS: 1.93 (-0.04), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Medtronic Unveils Favorable CoreValveEvolut R Study Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 1:10PM CDT
Medtronic plc (MDT) recently received favorable one-year data for its renowned transcatheter aortic valve replacement (TAVR) using the CoreValveEvolut R System.
MDT: 73.42 (-0.22), BAX: 35.60 (+1.34), NUVA: 48.61 (-1.31), HRC: 52.37 (+0.25)
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Baxter International Inc. Securities Litigation
PR Newswire - Thu Oct 15, 12:38PM CDT
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Baxter International Inc. Securities Litigation:
BAX: 35.60 (+1.34)
2 Top Stock Picks From Superstar Hedge Fund Investor Dan Loeb
at The Street - Thu Oct 15, 12:07PM CDT
Third Point's wily activist, known for blunt talk and stellar returns, has doubled down on Baxter International (BAX) and Mohawk Industries (MHK) this year.
BDX: 139.76 (unch), BCR: 189.65 (-2.72), MHK: 195.01 (-0.91), BAX: 35.60 (+1.34), BXLT: 31.73 (-0.36), BRK.B: 133.22 (-0.94), BRK.A: 199,900.00 (-1,580.00)
Baxter (BAX) Receives FDA Clearance for AMIA APD System
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 11:30AM CDT
Baxter International Inc. (BAX) recently announced that the FDA has approved its AMIA automated peritoneal dialysis (APD) system with the SHARESOURCE web-based remote connectivity platform.
NXTM: 15.55 (-0.18), BAX: 35.60 (+1.34), FMS: 42.31 (unch), NUVA: 48.61 (-1.31)
MacroGenics (MGNX) Looks Good: Stock Moves 5.5% Higher
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 7:40AM CDT
MacroGenics, Inc. (MGNX) saw its shares rise nearly 6% in the last trading session.
MGNX: 29.15 (+0.44), BAX: 35.60 (+1.34)
Shares of BAX Down 17.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 13, 11:35AM CDT
SmarTrend identified a Downtrend for Baxter International (NYSE:BAX) on August 19th, 2015 at $40.32. In approximately 2 months, Baxter International has returned 17.18% as of today's recent price of $33.40.
BAX: 35.60 (+1.34)
These Big Pharma Companies Are in Need of an Acquisition
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 13, 7:45AM CDT
Source: Flickr user Nguyen Hung Vu. Although we're officially over the "patent cliff" -- the multiple year period when dozens of innovator drugs came off patent and were exposed to generic competition -- Big Pharma is far from out of the woods when...
JNJ: 97.63 (+0.04), ISIS: 42.97 (+1.64), BAX: 35.60 (+1.34), PFE: 33.46 (-0.54), AZN: 30.47 (-0.46), ABBV: 53.83 (-1.00), BXLT: 31.73 (-0.36), GSK: 40.86 (-0.30), NVS: 91.59 (-0.74)
